PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsSkin neoplasms
MeSH D012878 - skin neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012871:Skin diseases
$
Success rate
D009371:Neoplasms by site
0 Companies
0 Drugs
Success rate
D012878: 
Skin neoplasms
$
Success rate
D012626:Sebaceous gland neoplasms
0 Companies
0 Drugs
Success rate
D013544:Sweat gland neoplasms
0 Companies
0 Drugs
Success rate
D034701:Cutaneous mastocytosis
0 Companies
0 Drugs
Success rate
D000096142:Cutaneous malignant melanoma
0 Companies
0 Drugs
Success rate
D008545:Melanoma
D049309:Acanthoma
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
GenentechVismodegib Erivedge 2025-09-02 2012-01-30   
Horizon Therapeutics PublicInterferon gamma-1b Actimmune  1999-02-25 $122.816 M Q3/22-Q2/23 
Merck & CoInterferon alfa-2b Intron A  1986-06-04   
Interferon alfa-2b IntronA  2000-03-09   
Interferon alfa-2b Viraferon  2000-03-09   
OrganonAlendronate, Cholecalciferol Fosamax D  2005-04-07   
Pharma&Peginterferon alfa-2a Pegasys  2002-10-16   
RocheVismodegib Erivedge  2013-07-12 $303.263 M Q4/22-Q3/23 
Ribavirin, Peginterferon alfa-2a Pegasys Copegus  2004-06-04   
Interferon alfa-2a Roferon-A  1986-06-04   
SandozFolic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol Infuvite  2000-05-18   
Sun Pharmaceutical IndustriesSonidegib Odomzo 2029-07-24 2015-07-24   
Clinical Trials
Historical Success Rate
Phase 1
53%
16/30
Phase 2
8%
6/71
Phase 3
50%
12/24
Approved: 8Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Genentech
Organon
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use